Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sonnet BioTherapeutics Holdings, Inc.

4.15
+2.94242.98%
Post-market: 4.10-0.0498-1.20%16:14 EDT
Volume:127.02M
Turnover:331.05M
Market Cap:13.14M
PE:-0.58
High:4.40
Open:1.30
Low:1.30
Close:1.21
Loading ...

Sonnet Biotherapeutics Announces $2 Million Convertible Note and Warrant Sale to Accredited Investors

Reuters
·
Yesterday

Sonnet Biotherapeutics Faces Nasdaq Listing Challenge Over Stockholders' Equity Compliance

Reuters
·
03 Jun

Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
17 May

Sonnet Biotherapeutics Holdings Inc expected to post a loss of 49 cents a share - Earnings Preview

Reuters
·
15 May

Sonnet BioTherapeutics Q2 EPS $(0.89) Misses $(0.79) Estimate

Benzinga
·
14 May

Sonnet Biotherapeutics Holdings Inc expected to post a loss of 92 cents a share - Earnings Preview

Reuters
·
10 May

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

GlobeNewswire
·
01 May

Sonnet Releases Virtual Investor "What This Means" Segment

GlobeNewswire
·
16 Apr

Sonnet BioTherapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
07 Apr

Sonnet BioTherapeutics Says Ovarian Cancer Drug Showed 'Positive' Safety Data in Phase 1b/2a Trial; Shares Up

MT Newswires Live
·
05 Apr

Sonnet Biotherapeutics Holdings Inc trading resumes

TIPRANKS
·
04 Apr

Sonnet says SON-1010 demonstrates ‘strong safety profile’ in atezolizumab combo

TIPRANKS
·
04 Apr

BRIEF-Sonnet’S Son-1010 Demonstrates A Strong Safety Profile In Combination With Atezolizumab For Treatment Of Platinum-Resistant Ovarian Cancer

Reuters
·
04 Apr

Sonnet Biotherapeutics Holdings Inc - Topline Safety Data Suggest Clinical Benefit of Son-1010 With Atezolizumab

THOMSON REUTERS
·
04 Apr

Sonnet’s Son-1010 Demonstrates a Strong Safety Profile in Combination With Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

THOMSON REUTERS
·
04 Apr

Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose

GlobeNewswire
·
04 Apr

Sonnet Biotherapeutics Holdings Inc trading halted, news pending

TIPRANKS
·
04 Apr

Sonnet Announces Release of Corporate Update Video

GlobeNewswire
·
02 Apr

BRIEF-Sonnet Announces The Passing Of Founder And CEO Pankaj Mohan

Reuters
·
01 Apr

Sonnet Biotherapeutics Holdings - Board Has Unanimously Approved Appointment of Raghu Rao as Interim CEO

THOMSON REUTERS
·
01 Apr